MONEY

Merck's KEYTRUDA ® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 00:00
Merck's KEYTRUDA ® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Read More

Tags:

Previous Article

Iran says it is open to talks but rejects pressure as US, EU impose sanctions

Next Article

Abbot Schröder elected Abbot Primate of Benedictine Confederation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

SciSparc extends $1.85 million loan to Automax

SciSparc extends $1.85 million loan to Automax

Tomas Kauer - Mode... Sep 11, 2024

JBG SMITH stock hits 52-week high at $18.18 amid market rally

JBG SMITH stock hits 52-week high at $18.18 amid market...

Tomas Kauer - Mode... Sep 14, 2024

China-Africa relations through young eyes

China-Africa relations through young eyes

Tomas Kauer - Mode... Sep 1, 2024